Harvard University, Interfaculty Initiative in Health Policy, Cambridge, Massachusetts.
Evidence for Access, Genentech Inc, South San Francisco, California.
JAMA Health Forum. 2021 Dec 3;2(12):e214044. doi: 10.1001/jamahealthforum.2021.4044. eCollection 2021 Dec.
Maternal and perinatal mortality remain high in the US despite growing rates of prenatal services and spending, and little rigorous evidence exists regarding the impact of prenatal care intensity on pregnancy outcomes. Patients with an expected date of delivery just after their 35th birthday may receive more intensive care owing to the advanced maternal age (AMA) designation; whether this increase in prenatal care is associated with improvements in outcomes has not been explored.
To determine the association between the AMA designation and prenatal care services, severe maternal morbidity, and perinatal mortality.
This cross-sectional study used a regression discontinuity design to compare individuals just above vs just below the 35-year AMA cutoff, using unidentifiable administrative claims data from a large, nationwide commercial insurer. All individuals with a delivery between January 1, 2008, and December 31, 2019, who were aged 35 years within 120 days of their expected date of delivery were included in the study. Analyses were performed from July 1, 2020, to February 1, 2021.
Individuals who were aged 35.0 through 35.3 years on the expected date of delivery were designated as AMA.
Outcomes were visits with specialists (obstetrician-gynecologists and maternal-fetal medicine), ultrasound scan use, antepartum fetal surveillance, aneuploidy screening, severe maternal morbidity, preterm birth or low birth weight, and perinatal mortality.
The analysis included 51 290 individuals (mean [SD] age; 34.5 [0.5] years); 26 108 individuals (50.9%) were aged 34.7 to 34.9 years and 25 182 individuals (49.1%) were aged 35.0 to 35.3 years on the expected date of delivery. A total of 2407 pregnant individuals (4.7%) had multiple gestation, 2438 (4.8%) had pregestational diabetes, 2265 (4.4%) had chronic hypertension, and 4963 (9.7%) had obesity. Advanced maternal age was associated with a 4.27 percentage point increase in maternal-fetal medicine visits (95% CI, 2.27-6.26 percentage points; < .001), a 0.21 unit increase in total ultrasound scans (95% CI, 0.06-0.37; = .006), a 15.67 percentage point increase in detailed ultrasound scans (95% CI, 13.68-17.66 percentage points; < .001), and a 4.86 percentage point increase in antepartum surveillance (95% CI, 2.83-6.89 percentage points; < .001). The AMA designation was associated with a 0.39 percentage point decline in perinatal mortality (95% CI, -0.77 to -0.01 percentage points; = .04).
In this cross-sectional study, the AMA designation at age 35 years was associated with an increase in receipt of prenatal monitoring and a small decrease in perinatal mortality, suggesting that the AMA designation may be associated with clinical decision-making, with individuals just older than 35 years receiving more prenatal monitoring. These results suggest that increases in prenatal care services stemming from the AMA designation may have important benefits for fetal and infant survival for patients in this age range.
尽管产前服务和支出的比例不断增加,但美国的孕产妇和围产期死亡率仍然很高,几乎没有严格的证据表明产前护理强度对妊娠结局的影响。预计预产期在 35 岁生日之后的患者可能会因为高龄产妇(AMA)的指定而接受更密集的护理;这种产前护理的增加是否与改善结果有关尚未得到探讨。
确定 AMA 标识与产前护理服务、严重产妇发病率和围产儿死亡率之间的关联。
设计、设置和参与者:这项横断面研究使用回归不连续性设计,使用来自一家大型全国性商业保险公司的不可识别行政索赔数据,比较了刚刚超过和刚刚低于 35 岁 AMA 截止值的个体。所有在 2008 年 1 月 1 日至 2019 年 12 月 31 日期间分娩的、预产期在 120 天内年龄为 35 岁的个体都包括在研究中。分析于 2020 年 7 月 1 日至 2021 年 2 月 1 日进行。
预计预产期在 35.0 至 35.3 岁的个体被指定为 AMA。
结果是与专家(妇产科医生和胎儿医学专家)的就诊次数、超声扫描使用、产前胎儿监测、非整倍体筛查、严重产妇发病率、早产或低出生体重以及围产儿死亡率。
分析包括 51290 名个体(平均[标准差]年龄;34.5[0.5]岁);26108 名个体(50.9%)的年龄为 34.7 至 34.9 岁,25182 名个体(49.1%)的预计预产期在 35.0 至 35.3 岁。共有 2407 名孕妇(4.7%)怀有多胎妊娠,2438 名(4.8%)患有孕前糖尿病,2265 名(4.4%)患有慢性高血压,4963 名(9.7%)患有肥胖症。高龄产妇与胎儿医学就诊次数增加 4.27 个百分点(95%CI,2.27-6.26 个百分点; < .001)、总超声扫描量增加 0.21 个单位(95%CI,0.06-0.37; = .006)、详细超声扫描增加 15.67 个百分点(95%CI,13.68-17.66 个百分点; < .001)和产前监测增加 4.86 个百分点(95%CI,2.83-6.89 个百分点; < .001)有关。AMA 标识与围产儿死亡率降低 0.39 个百分点(95%CI,-0.77 至-0.01 个百分点; = .04)相关。
在这项横断面研究中,35 岁时的 AMA 标识与产前监测的增加和围产儿死亡率的微小下降相关,这表明 AMA 标识可能与临床决策相关,刚刚超过 35 岁的个体接受更多的产前监测。这些结果表明,由于 AMA 标识而增加的产前护理服务可能对该年龄段患者的胎儿和婴儿存活有重要益处。